While Amgen's (NASDAQ: AMGN) shares have underperformed the market over the past 12 months, climbing 19.7% compared to the ...

As an aside, in the tech space, see What’s Happening With Snap Stock? Although the recent Amgen update didn’t bode well with ...

On STAT's podcast, hear about what happened with AbbVie's schizophrenia drug, Amgen's obesity drug and what might happen at ...

Amgen said on Wednesday there was no link between its experimental weight-loss drug and changes in bone density, a day after ...

Dramatic study results point to the potential for a steroid-sparing option for patients with the underrecognized multiorgan ...

The excitement around the new weight-loss industry is overtaking other disease areas and portfolios for publicly traded ...

After a research note raised potential safety concerns with Amgen's lead obesity candidate, the company defended its drug and ...

A hidden tab in an Excel spreadsheet published nine months ago has wiped $12 billion off Amgen’s market cap. The tab contains ...

Analysts cited data from a phase one study showing the highest dose of Amgen’s MariTide was linked to roughly 4% loss of bone ...

Shares of Amazon.com Inc. and Amgen are retreating Friday afternoon, sending the Dow Jones Industrial Average into negative territory.

Amgen (AMGN) announced the presentation of new data across its rare disease portfolio and pipeline at the annual American College of ...

(Reuters) -Amgen said on Wednesday there was no link between its experimental weight-loss drug and changes in bone density, a ...